Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Amcad Biomed's share price for the quarter that ended in Dec. 2025 was NT$14.7. Amcad Biomed's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 63.33 Mil. Therefore, Amcad Biomed's market cap for the quarter that ended in Dec. 2025 was NT$931.00 Mil.
Amcad Biomed's quarterly market cap
declined
from Jun. 2025 (NT$1,035.49 Mil) to Sep. 2025 (NT$968.99 Mil) and
declined
from Sep. 2025 (NT$968.99 Mil) to Dec. 2025 (NT$931.00 Mil).
Amcad Biomed's annual market cap
declined
from Dec. 2023 (NT$1,421.94 Mil) to Dec. 2024 (NT$1,415.49 Mil) and
declined
from Dec. 2024 (NT$1,415.49 Mil) to Dec. 2025 (NT$931.00 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Amcad Biomed's Enterprise Value for Today is NT$311.42 Mil.
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Amcad Biomed Market Cap Related Terms
Amcad Biomed Market Cap Historical Data
* Premium members only.
The historical data trend for Amcad Biomed's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Amcad Biomed's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amcad Biomed Market Cap vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Amcad Biomed's Market Cap distribution charts can be found below:
* The bar in red indicates where Amcad Biomed's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Amcad Biomed's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amcad Biomed (ROCO:4188) has a Market Cap of NT$598.50 Mil as of Aug. 01, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Amcad Biomed and its competitors. According to the industry distribution chart, Amcad Biomed ranks #665 out of 862 companies in the Medical Devices & Instruments industry, placing it in the top 77.1%.
Is Amcad Biomed's Market Cap too high?
Amcad Biomed's current Market Cap is NT$598.50 Mil. Based on the distribution chart, Amcad Biomed ranks #665 out of 862 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Amcad Biomed has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Amcad Biomed's Market Cap compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Amcad Biomed ranks #665 out of 862 companies for Market Cap. This places Amcad Biomed in the lower half of its industry. The industry median Market Cap is 113.83. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Devices & Instruments company?
The median Market Cap among Medical Devices & Instruments companies is 113.83, based on 862 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Amcad Biomed and its competitors. For the Medical Devices & Instruments industry, the median Market Cap is 113.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amcad Biomed's current Market Cap is NT$598.50 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amcad Biomed stock overvalued right now?
Based on GuruFocus' analysis, Amcad Biomed (ROCO:4188) is currently considered Fairly Valued. The stock's GF Value™ is NT$9.10, compared to a current price of NT$9.45 — trading 3.8% above its estimated fair value. The current Market Cap is NT$598.50 Mil. Amcad Biomed's overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Amcad Biomed (ROCO:4188), the current Market Cap is NT$598.50 Mil as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amcad Biomed (ROCO:4188) Overvalued in 2026?
Based on GuruFocus' analysis, Amcad Biomed stock appears to be overvalued.
The current stock price of NT$9.45 is trading 3.8% above its estimated GF Value™ of NT$9.10.
GuruFocus considers Amcad Biomed to be Fairly Valued.
Key valuation signals for ROCO:4188:
Market Cap: NT$598.50 Mil
GF Value™: NT$9.10 vs. price of NT$9.45 (3.8% above fair value)
No single metric tells the full story. See the ROCO:4188 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amcad Biomed Corp develops computer-aided detection and diagnosis(CADe/CADx) software devices. Its product pipeline includes AmCAD-UT Detection, AmCAD-UV, AmCAD and AmCAD-UO. Geographically, the company generates revenue from Taiwan, China, Europe, Asia (excluding Taiwan and China), and other countries, out of which the majority of the revenue is generated from Taiwan. The company has two segments: the Medical Diagnostic Software segment, which is responsible for the development and sales of smart medical imaging diagnostic software devices, and the Precision Medical Equipment segment, which is responsible for research, development, manufacturing, and sales of high-end ultrasonic probes. The company generates the majority of its revenue from the Precision Medical Equipment segment.
53GF Score
Get the complete analysis for ROCO:4188
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4188 has been successfully added to your 
